viewAllergy Therapeutics PLC

Allergy Therapeutics - Director Dealings and Issue of Equity

RNS Number : 5729B
Allergy Therapeutics PLC
09 October 2020



Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")


Director Dealings and Issue of Equity


9 October 2020 - Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that Manuel Llobet, Chief Executive Officer, has exercised 2,577,923  options over ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") ("Exercise") in aggregate, held under the terms of the Company's Long Term Incentive Plan. The 2,577,923 new Ordinary Shares issued pursuant to the Exercise ("New Ordinary Shares ") have been sold by Mr Llobet at a price of 15 pence per ordinary share ("Sale"). The sold shares represent approximately 28.6% of Mr Llobet 's total equity and option holdings in the Company's equity. This share sale is the first sale of any of Mr Llobet 's equity in the Company since joining in 2009 and he has no current intention of making further sales of Allergy Therapeutics shares.

Following the Exercise and Sale, Mr Llobet's holding of Ordinary Shares remains unchanged at a total of 3,325,000 Ordinary Shares, representing 0.52% of the enlarged issued share capital of the Company and following the Exercise, Mr Llobet holds a further 3,122,500 options and conditional awards over Company's ordinary shares of 0.1 pence each.

Total voting rights

The 2,577,923 New Ordinary Shares will be allocated out of the ordinary shares pursuant to the block listing announced on 21 November 2017. The New Ordinary Shares will rank pari passu with the existing shares of the Company. Following Admission, the Company's issued ordinary share capital will consist of 639,863,727 ordinary shares. The Company does not hold any shares in treasury. Therefore, the total number of ordinary shares with voting rights in the Company following Admission will be 639,863,727.

The above figure of 639,863,727 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.


The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.


Notification and public disclosure of transactions by persons discharging managerial responsibilities and/or persons closely associated with them:



Details of the person discharging managerial responsibilities/person closely associated




Manuel Llobet


Reason for the notification




Chief Executive Officer, Director


Initial notification/Amendment


Initial Notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



Allergy Therapeutics plc





Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


Description of the financial instrument, type of instrument


Identification code

0.1p ordinary shares





Nature of the transaction


Exercise of options and Sale of Ordinary Shares


Price(s) and volume(s)



Price(s) per Ordinary Share




15 pence

2,577,923 (option exercise)


2,577,923   (sale of ordinary shares)


Aggregated information









Date of the transaction


8 October 2020


Place of the transaction



London Stock Exchange - AIM





-   ENDS   -


For further information, please contact:


Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer


Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking


Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott, David Daley, Ashley Tapp, Olivia Manser

[email protected]


Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

[email protected]



Notes for editors:

About Allergy Therapeutics


Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.


Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

Quick facts: Allergy Therapeutics PLC

Price: -

Market: AIM
Market Cap: -

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Allergy Therapeutics on track for phase III grass pollen trial in 2019

Manuel Llobet, chief executive of Allergy Therapeutics plc (LON:AGY), spoke to Proactive Investors after reporting  “extremely positive results” from the phase II trial of their grass pollen-induced hay fever immunotherapy. Llobet says PQ Grass met its primary endpoint, with those...

on 21/5/18

6 min read